Technical Analysis for ADMS - Adamas Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 4.71 2.61% 0.12
ADMS closed down 7.83 percent on Tuesday, August 11, 2020, on 2.14 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical ADMS trend table...

Date Alert Name Type % Chg
Jack-in-the-Box Bullish Bullish Swing Setup 2.61%
Parabolic Rise Strength 2.61%
Upper Bollinger Band Walk Strength 2.61%
Inside Day Range Contraction 2.61%
Wide Bands Range Expansion 2.61%
Above Upper BB Strength 2.61%
Crossed Above 200 DMA Bullish -5.42%
Expansion Breakout Bullish Swing Setup -5.42%
Pocket Pivot Bullish Swing Setup -5.42%
Volume Surge Other -5.42%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Adamas Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for chronic disorders of the central nervous systems (CNS) in the United States. The company is developing its lead product candidate, ADS-5102 that has completed a Phase 2/3 clinical study for levodopa induced dyskinesia, a complication of Parkinson's disease; and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. It is also developing ADS-8800 and ADS-9000 series of products for use in a range of CNS indications; ADS-8704, a fixed-dose combination of memantine and donepezil for the treatment of moderate to severe dementia related to alzheimer's disease; and ADS-8902, a triple combination antiviral drug therapy for influenza. In addition, the company develops memantine-based therapeutics portfolio includes Namenda XR and MDX-8704, which are used in the treatment of dementia associated with moderate to severe alzheimer's disease. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Chemical Compounds Alzheimer's Disease Parkinson's Disease Influenza Psychiatric Diagnosis Mental Health Psychiatry Dementia Cognitive Disorders Treatment Of Alzheimer's Disease Drug Therapy Learning Disabilities Levodopa Induced Dyskinesia Traumatic Brain Injury

Is ADMS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 7.77
52 Week Low 1.9
Average Volume 694,308
200-Day Moving Average 3.89
50-Day Moving Average 2.79
20-Day Moving Average 2.88
10-Day Moving Average 3.13
Average True Range 0.34
ADX 24.3
+DI 55.99
-DI 5.05
Chandelier Exit (Long, 3 ATRs ) 4.37
Chandelier Exit (Short, 3 ATRs ) 3.45
Upper Bollinger Band 4.26
Lower Bollinger Band 1.50
Percent B (%b) 1.12
BandWidth 96.05
MACD Line 0.34
MACD Signal Line 0.10
MACD Histogram 0.2448
Fundamentals Value
Market Cap 103.34 Million
Num Shares 22.5 Million
EPS -2.99
Price-to-Earnings (P/E) Ratio -1.54
Price-to-Sales 2373.51
Price-to-Book 4.03
PEG Ratio -0.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.30
Resistance 3 (R3) 5.36 5.19 5.18
Resistance 2 (R2) 5.19 5.01 5.16 5.14
Resistance 1 (R1) 4.89 4.90 4.81 4.83 5.10
Pivot Point 4.72 4.72 4.68 4.69 4.72
Support 1 (S1) 4.42 4.54 4.34 4.36 4.08
Support 2 (S2) 4.25 4.43 4.22 4.04
Support 3 (S3) 3.95 4.25 4.00
Support 4 (S4) 3.89